These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 31140155)

  • 1. Radiation dosimetry and pharmacokinetics of florbetapir (
    Nakano M; Nakamura T; Takita Y; Uenaka K; Ando T; Senda M; Joshi AD; Lu M; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2019 Aug; 33(8):639-645. PubMed ID: 31140155
    [No Abstract]   [Full Text] [Related]  

  • 2. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
    Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
    Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
    Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
    Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
    Trembath L; Newell M; Devous MD
    J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Target Region for Subject Classification on the Basis of Amyloid PET Images.
    Carbonell F; Zijdenbos AP; Charil A; Grand'Maison M; Bedell BJ;
    J Nucl Med; 2015 Sep; 56(9):1351-8. PubMed ID: 26135108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
    Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
    Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of MRI-based Segmentation Artifacts on Amyloid- and FDG-PET Quantitation.
    Högenauer M; Brendel M; Delker A; Därr S; Weiss M; Bartenstein P; Rominger A; Alzheimer's Disease Neuroimaging Initiative
    Curr Alzheimer Res; 2016; 13(5):597-607. PubMed ID: 27025775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Florbetapir F 18 for brain imaging of β-amyloid plaques.
    Romano M; Buratti E
    Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease.
    Kobylecki C; Langheinrich T; Hinz R; Vardy ER; Brown G; Martino ME; Haense C; Richardson AM; Gerhard A; Anton-Rodriguez JM; Snowden JS; Neary D; Pontecorvo MJ; Herholz K
    J Nucl Med; 2015 Mar; 56(3):386-91. PubMed ID: 25655625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
    Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
    J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
    Okamura N; Yanai K
    IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
    Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
    Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal pulmonary
    Pittman S; Sethi P; Flavell RR; De Marco T; Hernandez Pampaloni M
    J Nucl Cardiol; 2018 Oct; 25(5):1865-1868. PubMed ID: 29101671
    [No Abstract]   [Full Text] [Related]  

  • 20. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
    Carome M; Wolfe S
    JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.